Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 January 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Effect of the GABAB agonist baclofen on symptoms of GERD

The GABAB agonist baclofen reduces 24 hour gastro-esophageal reflux and increases gastric pH in patients with GERD, finds a research team in the April issue of Gut.

News image

fiogf49gjkf04

The gamma-aminobutyric acid (GABAB) agonist baclofen reduces reflux episodes in the first 3 postprandial hours. This occurs in both patients with gastro-esophageal reflux disease (GERD) and in normal controls.

In this study, researchers from Italy assessed acute and chronic administration of baclofen on 24-hour pH metry and symptoms in GERD patients and normal controls.

In the acute study, the team assessed 28 patients with GERD, and none or mild esophagitis at endoscopy. They also assessed 15 controls.

Baclofen or placebo were administered for 24 hours in a double blinded manner.

In the acute study, gastric pH increased significantly in both groups.
Gut

Subjects underwent esophageal and gastric 48-hour pH metry.

In the chronic study, 16 GERD patients received baclofen (10 mg 4 times daily) or placebo for 4 weeks.

The team evaluated 24-hour esophageal pH metry and reflux symptom scores before and after treatment.

In the acute study, researchers found that the number of reflux episodes and percent of time with pH < 4 was significantly lower after baclofen in both GERD patients and controls.

In addition, gastric pH increased significantly in both groups.

In the chronic study, the team found that 4 weeks after initial administration of baclofen, the number of reflux episodes and percentage of time with pH < 4 significantly decreased in all GERD patients.

In addition, symptom scores significantly improved after treatment with baclofen.

Profs. Ciccaglione and Marzio concluded, "The GABAB agonist baclofen reduces 24 hour gastro-esophageal reflux and increases gastric pH in GERD patients and controls".

"When given for 1 month to GERD patients, baclofen reduces esophageal acid refluxes and significantly improves symptoms."

"Baclofen may be useful in the therapy of GERD."

Gut 2003; 52: 464-70
14 March 2003

Go to top of page Email this page Email this page to a colleague

 18 January 2017 
Measure of GERD
 18 January 2017 
Helicobacter pylori eradication and insulin resistance
 18 January 2017 
Hormone levels and NAFLD severity
 17 January 2017 
Pediatric-onset Crohn's disease
 17 January 2017 
Biologic drugs and extraintestinal manifestations in IBD
 17 January 2017 
Colorectal cancer prevention among Medicare beneficiaries
 16 January 2017 
HCV eradication in cirrhosis
 16 January 2017 
Thyroid and primary biliary cholangitis
 16 January 2017 
Sarcopenia and severe liver fibrosis
 13 January 2017 
Early monocytopenia in paracetamol-induced liver failure
 13 January 2017 
Anti-TNF discontinuation in patients with IBD
 13 January 2017 
Isolated colonic Crohn's disease
 12 January 2017 
Providing relief for chronic constipation
 12 January 2017 
Internet-delivered therapy for adolescents with IBS
 12 January 2017 
NAFLD and coronary artery calcium score
 11 January 2017 
Fatigue in IBD
 11 January 2017 
Pancreatic cancer risk with asthma and nasal allergies
 11 January 2017 
PPIs and bone strength and structure
 10 January 2017 
Colorectal cancer risk in serrated polyposis syndrome
 10 January 2017 
Evaluation of abnormal liver chemistries
 10 January 2017 
Pelvic physiotherapy in functional constipation
 09 January 2017 
Intestinal microbiota and IBS
 09 January 2017 
Helicobacter and Campylobacter in IBD
 09 January 2017 
Diagnosis of microscopic colitis
 06 January 2017 
Recommendations on colorectal cancer screening 
 06 January 2017 
Colorectal cancer susceptibility gene variants
 06 January 2017 
Thiopurine-induced hepatotoxicity in IBD
 05 January 2017 
Histological index for ulcerative colitis
 05 January 2017 
Crohn's disease after total colectomy with permanent ileostomy
 05 January 2017 
Celiac disease screening in IBS
 04 January 2017 
Serrated colorectal polyps risk factors
 04 January 2017 
Score to predict eosinophilic esophagitis
 04 January 2017 
Platelet transfusion for gastrointestinal bleeding
 03 January 2017 
Pelvic physiotherapy for functional constipation in children
 03 January 2017 
Tumor necrosis factor antagonists in IBD
 03 January 2017 
Mesenchymal stromal cell therapy for IBD
 22 December 2016 
Happy holidays!
 21 December 2016 
Pharmacotherapy for NAFLD
 21 December 2016 
Predicting disease activity in eosinophilic esophagitis
 21 December 2016 
Breath Testing for Barrett’s esophagus
 20 December 2016 
H. pylori on the ethnic distribution of Barrett's metaplasia
 20 December 2016 
Prognostic biomarker in colorectal cancer
 20 December 2016 
Online health information for colorectal cancer screening
 19 December 2016 
Risk of tuberculosis in IBD
 19 December 2016 
Risk of complications of percutaneous liver biopsy
 19 December 2016 
Hospital research and colorectal cancer survival
 16 December 2016 
Mortality rates for major causes of death
 16 December 2016 
Non-invasive genomic biomarkers for colorectal cancer
 16 December 2016 
Predicting organ failure in acute pancreatitis
 15 December 2016 
Adjuvant chemotherapy use varies for advance colon cancer
 15 December 2016 
Histological index for ulcerative colitis
 15 December 2016 
Readmission after acute upper GI bleed
 14 December 2016 
Fecal microbiota transfer
 14 December 2016 
Colorectal cancer screening in primary care
 14 December 2016 
Management of H. pylori infection
 13 December 2016 
Caffeine and hepatitis C virus infection
 13 December 2016 
Clinical relapse among patients with ulcerative colitis
 13 December 2016 
Features of asymptomatic erosive esophagitis
 12 December 2016 
Colorectal cancer prevention
 12 December 2016 
Precision medicine in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us